[Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
Sixteen patients with previously untreated acute nonlymphocytic leukemia were treated with a combination of aclacinomycin A (ACM-A) and behenoyl ara-C (BH-AC) at Saitama Cancer Center between April 1980 and February 1983. The complete remission was obtained in 10 of 16 patients (62.5%) (M1, 0/1 M2, 8/8, M3, 0/2, M4, 2/5). A combination of daunorubicin (DNR) and cytosine arabinoside (ARA-C) was crossed over to 5 patients who failed to respond to primary treatment of a combined ACM-A and BH-AC. All of these attained the complete remission. The cumulative dose of over 600 mg/m2 of ACM-A has been given to 7 patients as maintenance treatment. The maximum cumulative dose was 2000 mg/m2. The median survival time for all patients was 12 months, and the median survival with complete remission has not been reached; however, it is estimated to be greater than 24 months. ACM-A seemed to induce long-term maintenance when it was used as maintenance treatment. The results have demonstrated that a combination of ACM-A and BH-AC shows equivalent activity with that of a combined DNR and ARA-C in terms of remission induction and remission maintenance.
D015250:Aclarubicin; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D003561:Cytarabine; D015250:Aclarubicin; C015019:enocitabine